Walleye Capital’s Axsome Therapeutics AXSM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$170K Sell
920
-796
-46% -$173K ﹤0.01% 4917
2026
Q2
$420K Sell
1,716
-33,403
-95% -$7.24M ﹤0.01% 2899
2026
Q1
$5.94M Sell
35,119
-24,981
-42% -$4.31M 0.02% 701
2025
Q4
$11M Buy
60,100
+59,600
+11,920% +$8.32M 0.03% 595
2025
Q3
$60.7K Sell
500
-1,783
-78% -$201K ﹤0.01% 3930
2025
Q2
$238K Buy
2,283
+697
+44% +$73.8K ﹤0.01% 3224
2025
Q1
$185K Sell
1,586
-377
-19% -$43K ﹤0.01% 3322
2024
Q4
$166K Sell
1,963
-44,775
-96% -$4.12M ﹤0.01% 3874
2024
Q3
$4.2M Sell
46,738
-29,285
-39% -$2.56M 0.01% 1312
2024
Q2
$6.12M Sell
76,023
-21,097
-22% -$1.56M 0.01% 1143
2024
Q1
$7.75M Buy
+97,120
New +$8.15M 0.01% 996
2023
Q3
– Sell
-86,280
Closed -$6.45M – 4857
2023
Q2
$6.2M Buy
+86,280
New +$6.36M 0.02% 616
2022
Q2
– Sell
-8,295
Closed -$343K – 2354
2022
Q1
$343K Buy
+8,295
New +$257K 0.01% 1228
2020
Q1
– Sell
-170,268
Closed -$17.6M – 942
2019
Q4
$17.6M Buy
+170,268
New +$6.88M 1.14% 2
2018
Q3
$62K Buy
+17,838
New +$52.9K 0.03% 276

Other funds holding AXSM

Walleye Capital's AXSM Position: Q3 2026 in Review

Walleye Capital reduced its Axsome Therapeutics (AXSM) stake by 46% in Q3 2026, selling an estimated $173K and leaving 920 shares worth $170K. The position accounts for ﹤0.01% of the portfolio, ranked #4917.

Walleye Capital first reported a position in AXSM in Q3 2018 and has held it in 15 quarters since. The position peaked at $17.6M in Q4 2019. 348 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

  • Walleye Capital held 920 shares of Axsome Therapeutics worth $170K as of Q3 2026.
  • Walleye Capital sold 796 Axsome Therapeutics shares in Q3 2026, an estimated $173K.
  • Axsome Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q3 2026, its #4917 holding.
  • Walleye Capital first reported a position in Axsome Therapeutics in Q3 2018 and has held it in 15 quarters since.
  • Walleye Capital's Axsome Therapeutics position peaked at $17.6M in Q4 2019.
  • 348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Walleye Capital's 13F filing for Q3 2026, filed 13 Nov 2026.